Adaptive Biotechnologies ADPT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $295.41M+55.9% | $276.98M+54.8% | $252.75M+42.6% | $205.22M+21.6% | $189.53M+8.6% | ||
| $73.09M+2.9% | $71.36M-1.0% | $71.18M-3.4% | $69.69M-8.7% | $71.01M-5.2% | ||
| $222.32M+87.6% | $205.62M+92.4% | $181.57M+75.2% | $135.53M+46.6% | $118.52M+19.0% | ||
| 75.3%+12.7pp | 74.2%+14.5pp | 71.8%+13.4pp | 66%+11.3pp | 62.5%+5.5pp | ||
| $93.19M-3.8% | $93.77M-8.9% | $95.2M-12.3% | $95.69M-15.2% | $96.91M-19.1% | ||
| $97.87M+14.5% | $94.57M+11.6% | $91.67M+7.7% | $88.75M+4.4% | $85.49M-3.5% | ||
| $76.29M+8.0% | $72.7M-0.1% | $71.2M-5.7% | $70.5M-10.0% | $70.61M-14.6% | ||
| $1.7M0.0% | $1.7M-0.2% | $1.7M-0.4% | $1.7M-0.4% | $1.7M-0.2% | ||
| $342.13M+2.8% | $334.1M-2.2% | $330.94M-12.2% | $326.33M-15.6% | $332.92M-15.3% | ||
| -$46.73M+67.4% | -$57.12M+64.9% | -$78.19M+60.9% | -$121.11M+44.5% | -$143.39M+34.4% | ||
| -15.8%+59.8pp | -20.6%+70.2pp | -30.9%+81.8pp | -59%+70.2pp | -75.7%+49.6pp | ||
| $8.85M-31.9% | $9.44M-35.0% | $10.37M-35.5% | $11.62M-31.2% | $12.99M-22.3% | ||
| -$49.68M+65.0% | -$59.5M+62.7% | -$79.61M+59.2% | -$121.23M+43.2% | -$141.84M+34.0% | ||
| -16.8%+58.0pp | -21.5%+67.6pp | -31.5%+78.6pp | -59.1%+67.4pp | -74.8%+48.4pp | ||
| -$0.33+65.3% | -$0.40+63.0% | -$0.53+60.4% | -$0.81+44.9% | -$0.95+36.2% | ||
| -$0.33+65.3% | -$0.40+63.0% | -$0.53+60.4% | -$0.81+44.9% | -$0.95+36.2% | ||
| 622.5M+5.3% | 616.2M+4.8% | 611.5M+4.5% | 595.9M+2.3% | 591.2M+2.1% | ||
| 611.8M+3.5% | 605.4M+3.0% | 600.8M+2.7% | 595.9M+2.3% | 591.2M+2.1% | ||
| $1.7M0.0% | $1.7M-0.2% | $1.7M-0.4% | $1.7M-0.4% | $1.7M-0.2% | ||
| $8.85M-31.9% | $9.44M-35.0% | $10.37M-35.5% | $11.62M-31.2% | $12.99M-22.3% | ||
| $295.41M+55.9% | $276.98M+54.8% | $252.75M+42.6% | $205.22M+21.6% | $189.53M+8.6% | ||
| -$46.73M+67.4% | -$57.12M+64.9% | -$78.19M+60.9% | -$121.11M+44.5% | -$143.39M+34.4% | ||
| -$29.79M+76.1% | -$39.29M+72.6% | -$60.1M+66.5% | -$102.84M+47.7% | -$124.62M+36.6% | ||
| -$29.79M+76.1% | -$39.29M+72.6% | -$60.1M+66.5% | -$102.84M+47.7% | -$124.62M+36.6% | ||
| -10.1%+55.7pp | -14.2%+65.9pp | -23.8%+77.5pp | -50.1%+66.5pp | -65.8%+46.9pp | ||
| -$46.73M+67.4% | -$57.12M+64.9% | -$78.19M+60.9% | -$121.11M+44.5% | -$143.39M+34.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Adaptive Biotechnologies's revenue?
- Adaptive Biotechnologies (ADPT) generated $295.4M in revenue over the trailing twelve months, up 55.9% year over year.
- Is Adaptive Biotechnologies profitable?
- Adaptive Biotechnologies is not currently profitable: it reported a net loss of $49.7M over the trailing twelve months, a -16.8% net margin.
- What are Adaptive Biotechnologies's profit margins?
- Gross margin is 75.3% and operating margin is -15.8%, with a -16.8% net margin.
- What is Adaptive Biotechnologies's earnings per share?
- Adaptive Biotechnologies's diluted EPS over the trailing twelve months is $-0.33.
- Where does Adaptive Biotechnologies's income statement data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
